AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:32:29 29/06/2024 am IST			5-day change	1st Jan Change
171.5 ^USD	+1.50%		+0.66%	+10.68%

28/06	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT
28/06	AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	MT

AbbVie: acquisition of Celsius for $250 million

June 27, 2024 at 07:57 pm IST

On Thursday, AbbVie announced the acquisition of US biotech company Celsius Therapeutics for $250 million in cash.

The Chicago-based pharmaceutical group says the deal will give it access to the drug candidate CEL383, an antibody currently in Phase 1 clinical trial for the treatment of inflammatory bowel disease.

The compound belongs to the class of antibodies acting on TREM-1, a membrane receptor mainly expressed by myeloid cells that amplifies inflammation.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about AbbVie Inc.

Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	28/06	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	28/06	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	28/06	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	28/06	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	28/06	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	27/06	MT
AbbVie: acquisition of Celsius for $250 million	27/06	CF
AbbVie Buys Celsius Therapeutics for $250 Million	27/06	DJ
AbbVie Buys Celsius Therapeutics for $250 million	27/06	MT
AbbVie Buys Celsius Therapeutics for $250 million	27/06	MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal	27/06	MT
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	27/06	MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	27/06	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06	CI
AbbVie Inc. acquired Celsius Therapeutics, Inc. for $250 million.	27/06	CI
AbbVie Gets New FDA Accelerated Approval for Epkinly	27/06	DJ
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo -- Update	25/06	DJ
AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease	25/06	MT
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo	25/06	DJ
US FDA declines to approve AbbVie's Parkinson's disease therapy	25/06	RE
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	25/06	CI
AbbVie Keeps Quarterly Dividend at $1.55 per Share, Payable Aug. 15 to Shareholders of Record July 15	21/06	MT
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024	21/06	CI
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis	20/06	MT
US FDA proposes to remove switching study requirement for biosimilars	20/06	RE

Chart AbbVie Inc.

Duration

Period

More charts

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

15/07/2024 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

171.5 USD

Average target price

183.2 USD

Spread / Average Target

+6.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+10.68%	303B
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B
SANOFI	+0.20%	120B

Other Pharmaceuticals

AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

AbbVie: acquisition of Celsius for $250 million

EPS Revisions